Recombinant Vaccines Market
Recombinant vaccines are produced by using recombinant DNA technology or genetic engineering for the prevention of lethal diseases in human beings and animals. Recombinant vaccine is a biological preparation that provides active acquired immunity against a certain disease. Whereas individual being vaccinated produces antibodies against the protein antigen that protect a person from contracting the disease upon attack from the pathogenic microorganism. These vaccines functions on the immune response for diseases and to have preventive measures against diseases caused by various bacteria, and virus. These vaccines are much more advanced and effective as compare to conventional vaccines in the prevention of diseases such as malaria, typhoid, and human papillomavirus (HPV). Furthermore, Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and major demand for livestock products in Europe.
According to World Health Organization (WHO), around 18 million fatalities were caused due to inaccessibility of treatment for their illness. According to World Health Organization Report 2017, in the U.S. it is possible to prevent 2 million - 3 million deaths every year by immunization and 1.5 million deaths are easily avoided by immunization. There were around 19.5 million infants did not get basic vaccine. There is constant development in technology which lead to the manufacture of more effective vaccines for disease and companies are working for the development of new vaccines for various disease such as zika virus, cancer and others.
The global recombinant vaccine market was valued at US$ 830.2 million in 2016 and is expected to witness a robust CAGR of 6.0% during the forecast period (2017 – 2025).
Global Recombinant Vaccines Market (US$ Mn) by Geography- 2017
Increase in the incidence of zoonotic diseases and emerging technologies expected to support the growth of recombinant vaccines market
There is a constant increase in diseases caused by bacteria or virus such as swine flu, malaria, HPV and other diseases, which has raised the demand of vaccination and lead to the eradication of diseases such as polio, and tetanus in few countries. Whit the development in technology there is development in vaccines, which are more effective than conventional vaccines and does not lead to any side effect. These vaccines are easy to administer in the body orally, intramuscular or intradermal. In the U.S. there were around 212 million malaria cases and 429,000 deaths from malaria is reported in 2015. According to Centers for Disease Control and Prevention report 2017, in the U.S. there were around 49.9% of the children between the ages of 6 months to 17 years received an influenza vaccine.
Continuous investment in research & development for the development of new vaccines and increased awareness and pet adoption are expected to fuel the growth of recombinant vaccines
There are various companies working on the development of vaccine for various disease, which have affected human beings in short span of time such as Ebola, Zika, and H1N1 flu. The companies also working for the development of cancer vaccines different type of cancer includes lung cancer, blood cancer, skin cancer, bladder cancer, brain cancer, kidney cancer, prostate cancer, solid tumors cancer , breast cancer are the target area for recombinant vaccine development, which may expected to support the growth of recombinant vaccine market in the near future. In 2012, according to the World Cancer Research Fund International, globally around 1.7 million new cases of breast cancer are diagnosed. Breast cancers are being targeted in active NCI supported cancer prevention or treatment clinical trials using vaccines. The vaccine therapy with or without trastuzumab in treating patients with stage IV breast cancer is in phases II clinical trial. The folate receptor alpha peptide vaccine with GM-CSF in patient with triple negative breast cancer trial phase II. According to National Cancer Institute, in the U.S. there were around 1,685,210 new cases of cancer was reported and 595,690 people died from cancer in 2016. According to American Society for the Prevention of Cruelty to Animals, in the U.S. there were around 3.2 million shelter animals are adopted each year (1.6 million dogs and 1.6 million cats) and adoption of pets are expected to increase, which in turn raise the demand for recombinant vaccines for animals in near future.
Some major key players in the recombinant vaccines market include Merck & Co. Inc., Novartis AG, Protein Science Corporation, GlaxoSmithKline Plc., Green Cross Corporation, Bayer AG, Sanofi S A, Pfizer Inc., and Bharat Biotech.
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease. These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue. Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms. There is increase in the demand for livestock products, which in turn has increased growth of the animal recombinant vaccine segment and Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and huge demand of livestock product for the European population. According to Global Agriculture report, there were around 315 million tons of meat produced worldwide in 2014 and expected to increase to 318.8 million tons in 2015.
The recent past has witnessed a steady rise in incidence of zoonotic and infectious diseases in humans and animals as well, which lead to the increased research & developments for the innovation of new and effective recombinant vaccines for the prevention of diseases. Government has also taken an initiative to increase awareness regarding vaccination to prevent diseases in community. Manufacturing companies have also started some beneficial programs to provide vaccination free of cost to poor people, which creates a highly conducive environment for growth of the recombinant vaccines market in near future.
National Immunization Program by Queensland Government in Australia and Indradhanush vaccination program in India works to provide vaccination among children throughout the nation. Various organizations such as World Health Organization, World Bank, and United Nations Children’s Funds has also taken and initiative to increase vaccination.
The report segments the global recombinant vaccines market on basis of product type, end user, disease type and geography. On the basis of product type, the market is categorized into subunit recombinant vaccines, attenuated vaccines, and vector recombinant vaccines. Among these, the vector recombinant vaccines segment dominates the recombinant vaccines market throughout the forecast period. On the basis of disease type, the market is categorized into infectious disease, cancer, allergy, and others. On the basis of end user, the market is categorized into recombinant human vaccines and animal recombinant vaccines. On the basis of geography, the market is divided into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among all regions, North America contributes major market share supported by increased awareness among people and increase in infectious and viral diseases.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 36 market data tables and 107 figures on "Recombinant Vaccines(CGM) Market - Global forecast to 2025”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.